SOURCE: Burrill & Company

Burrill & Company

April 29, 2013 08:45 ET

Burrill Securities Launches Institutional Breakthrough Series

Inaugural Event in New York City to Focus on Gene Therapy

NEW YORK, NY--(Marketwired - Apr 29, 2013) - Gene therapy holds the promise of correcting genetic defects by providing a novel, one-time treatment, or by obviating the need for further chronic protein therapy. Burrill Securities today announced its inaugural Institutional Investor Breakthrough Series: Technology Shaping Tomorrow's Healthcare, which will focus on gene therapy.

While the concept of therapeutic gene modification arose more than forty years ago, with the first human subject treated in 1980, it took this long for the field to generate robust, lasting clinical impact with attractive safety profiles in numerous indications.

"With the European approval of Glybera, the first gene therapy approved in the western world, we are at an exciting time for this emerging sector," says Stephen Hurly, CEO of Burrill Securities. "We've seen waves of enthusiasm toward gene therapy surge and then quickly recede with high profile setbacks. This meeting will examine what's different now and why Big Pharma and Big Biotech have growing interests in the area."

Scientific founders and executives representing 10 companies will complement the review of the field by providing proof-of-concept, preclinical data, and human trial results. The symposium will include panel discussions on valuing gene therapy and on the current interests pharmaceutical companies have demonstrated in forging partnerships to access such therapies. Presenters include luminaries who helped to lay the foundation for the field and continue to galvanize it.

They include:
Jörn Aldag, CEO of uniQure
Larry Altstiel, MD, PhD, CEO of ProVectra
Reni Benjamin, PhD, Managing Director & Senior Equity Research Analyst of Burrill Securities
G. Steven Burrill, CEO of Burrill & Company
Robert Coffin, MD, Founder of BioVex
Boro Dropulic, PhD, MBA, Founder, President & CSO of Lentigen
Roger Hajjar, MD, PhD, Co-founder of Celladon
Edward Lanphier, President & CEO of Sangamo BioSciences, Inc.
Sheila Mikhail, JD, MBA, Co-founder of NanoCor & Asklepios
Elemer Piros, PhD, Managing Director of Burrill Securities
R. Jude Samulski, PhD, Co-founder of Asklepios
Samuel Wadsworth, PhD, Head, Gene Therapy R&D, Sanofi Genzyme R&D Center
Sue Washer, MBA, President & CEO of AGTC

The day-long meeting will be held Tuesday, April 30 at The St. Regis New York at 2 East 55th Street.

The free event is open only to institutional investors. You must be pre-registered for this event to attend. Seating is extremely limited. Please contact Jennifer Gregoire at 925-998-2304 or

About Burrill Securities LLC

Burrill Securities provides life sciences companies with access to financial resources through global capital and a complementary blend of financial advisory services on public and private financings and cross-border transactions, including M&A, strategic partnerships, spinouts, and public and private capital raising. It provides companies enhanced access to public market investors through its Institutional Equities business. Our team has extensive experience and a comprehensive global network to help life sciences companies access capital and strategic partners to build their businesses. Burrill Securities LLC, member FINRA/SIPC is the investment banking arm of Burrill & Company (

Contact Information

  • Contact:
    Daniel Levine
    Managing Director
    Burrill & Company
    Email Contact